{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:48:27Z","timestamp":1764604107073,"version":"3.40.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016321","name":"First Clinical Medical School, Lanzhou University","doi-asserted-by":"publisher","award":["grant no. ldyyyn2023-56"],"award-info":[{"award-number":["grant no. ldyyyn2023-56"]}],"id":[{"id":"10.13039\/501100016321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nObjective<\/jats:title>\nThe impact of acetazolamide (ACZ) in chronic mountain sickness (CMS) has not been fully assessed. The purpose of this systematic review is to evaluate the effectiveness and safety of acetazolamide in the treatment of chronic mountain sickness.<\/jats:p>\n<\/jats:sec>\n\nResearch methods<\/jats:title>\nThis systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The primary outcome measure was CMS clinical score. Secondary outcomes included CMS total score,hematocrit (HCT), Pondus Hydrogenii\u200c (pH), arterial oxygen pressure (PaO2), arterial carbon dioxide pressure (PaCO2), bicarbonate concentration (HCO3), and adverse events.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nFive randomized controlled trials were included, comprising a total of 137 subjects, with 78 in the acetazolamide group and 59 in the control group.The CMS clinical score showed an MD of \u22120.31 (95% CI, \u22121.13 to \u22120.51, P\u2009=\u20090.46),the results indicated no statistical significance.But the CMS total score had an MD of \u22121.13 [95% CI, \u22122.03 to \u22120.23], P\u2009=\u20090.01, showing a significant difference.The HCT results showed an MD of \u22122.70 (95% CI, \u22124.58 to \u22120.82; P\u2009=\u20090.005), indicating a statistically significant reduction. The result of PaO2,PaCO2,pH and HCO3 are statistically significant. In terms of adverse events, increased diuresis and headache were not statistically significant. Paresthesia had a significant difference.<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nBased on the available evidence, we conclude that ACZ 250 mg is a safe, reliable, and low-cost treatment option for chronic mountain sickness. By reducing HCT, PaCO2, pH, and HCO3, and increasing PaO2, it improves respiratory and circulatory parameters in CMS patients and effectively treats CMS.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0319689","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:27:54Z","timestamp":1742318874000},"page":"e0319689","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and safety of acetazolamide in chronic mountain sickness: A systematic review and meta\u2010analysis of randomized controlled trials"],"prefix":"10.1371","volume":"20","author":[{"given":"Yaqin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengcai","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9313-1901","authenticated-orcid":true,"given":"Zhouzhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"2456","key":"pone.0319689.ref001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1126\/science.95.2456.79","article-title":"Life in the andes and chronic mountain sickness","volume":"95","author":"C Monge","year":"1942","journal-title":"Science"},{"key":"pone.0319689.ref002","first-page":"S79-81","article-title":"Pathophysiology and epidemiology of chronic mountain sickness","author":"C Monge-C","year":"1992","journal-title":"Int J Sports Med"},{"key":"pone.0319689.ref003","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4615-4711-2_27","article-title":"International consensus group on chronic mountain sickness","volume":"474","author":"F Leon-Velarde","year":"1999","journal-title":"Adv Exp Med Biol"},{"issue":"17","key":"pone.0319689.ref004","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/eurjpc\/zwac166","article-title":"Cardiac remodelling in the highest city in the world: effects of altitude and chronic mountain sickness","volume":"29","author":"S Doutreleau","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"pone.0319689.ref005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1152\/japplphysiol.00439.2022","article-title":"Preserved peak exercise capacity in Andean highlanders with excessive erythrocytosis both before and after isovolumic hemodilution","volume":"134","author":"C Anza-Ram\u00edrez","year":"2023","journal-title":"J Appl Physiol (1985)"},{"issue":"6","key":"pone.0319689.ref006","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1152\/japplphysiol.00973.2020","article-title":"Time course and magnitude of ventilatory and renal acid-base acclimatization following rapid ascent to and residence at 3,800 m over nine days","volume":"130","author":"JD Bird","year":"2021","journal-title":"J Appl Physiol (1985)"},{"issue":"6","key":"pone.0319689.ref007","doi-asserted-by":"crossref","first-page":"1802040","DOI":"10.1183\/13993003.02040-2018","article-title":"Pulmonary arterial pressure at rest and during exercise in chronic mountain sickness: a meta-analysis","volume":"53","author":"R Soria","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"pone.0319689.ref008","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/1527029041352090","article-title":"Chronic mountain sickness: recent studies of the relationship between hemoglobin concentration and oxygen transport","volume":"5","author":"JT Reeves","year":"2004","journal-title":"High Alt Med Biol"},{"issue":"20","key":"pone.0319689.ref009","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMra1612008","article-title":"Physiological Effects of Chronic Hypoxia","volume":"376","author":"JB West","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0319689.ref010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/ham.2005.6.147","article-title":"Consensus statement on chronic and subacute high altitude diseases","volume":"6","author":"F Le\u00f3n-Velarde","year":"2005","journal-title":"High Alt Med Biol"},{"issue":"1","key":"pone.0319689.ref011","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12920-023-01613-9","article-title":"Changes in expression levels of erythrocyte and immune-related genes are associated with high altitude polycythemia","volume":"16","author":"S Feng","year":"2023","journal-title":"BMC Med Genomics"},{"issue":"9","key":"pone.0319689.ref012","doi-asserted-by":"crossref","first-page":"e1001116","DOI":"10.1371\/journal.pgen.1001116","article-title":"Identifying signatures of natural selection in Tibetan and Andean populations using dense genome scan data","volume":"6","author":"A Bigham","year":"2010","journal-title":"PLoS Genet"},{"issue":"20","key":"pone.0319689.ref013","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1101\/gad.250167.114","article-title":"Human high-altitude adaptation: forward genetics meets the HIF pathway","volume":"28","author":"AW Bigham","year":"2014","journal-title":"J Genes Dev"},{"issue":"2\u20133","key":"pone.0319689.ref014","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.resp.2007.05.003","article-title":"Treatment of chronic mountain sickness: critical reappraisal of an old problem","volume":"158","author":"M Rivera-Ch","year":"2007","journal-title":"J Respir Physiol Neurobiol"},{"issue":"11","key":"pone.0319689.ref015","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1113\/EP089975","article-title":"Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness","volume":"106","author":"JL Macarlup\u00fa","year":"2021","journal-title":"J Exp Physiol"},{"key":"pone.0319689.ref016","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/978-94-007-7359-2_18","article-title":"Carbonic anhydrase inhibitors and high altitude illnesses","volume":"75","author":"ER Swenson","year":"2014","journal-title":"Subcell Biochem"},{"issue":"1","key":"pone.0319689.ref017","doi-asserted-by":"crossref","first-page":"e0022","DOI":"10.5041\/RMMJ.10022","article-title":"High-altitude illnesses: physiology, risk factors, prevention, and treatment","volume":"2","author":"AT Taylor","year":"2011","journal-title":"Rambam Maimonides Med J"},{"issue":"1","key":"pone.0319689.ref018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/ham.2019.0123","article-title":"Altitude, Acute Mountain Sickness, and Acetazolamide: Recommendations for Rapid Ascent","volume":"22","author":"CM Toussaint","year":"2021","journal-title":"High Alt Med Biol"},{"key":"pone.0319689.ref019","article-title":"Acetazolamide","volume-title":"StatPearls","author":"K Farzam","year":"2023"},{"issue":"11","key":"pone.0319689.ref020","first-page":"953","article-title":"The preventive effect of four drugs on acute mountain sickness: a Bayesian network meta-analysis","volume":"44","author":"HL Yang","year":"2021","journal-title":"J Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"5","key":"pone.0319689.ref021","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.amjms.2020.12.022","article-title":"Efficacy of Acetazolamide for the Prophylaxis of Acute Mountain Sickness: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials","volume":"361","author":"D Gao","year":"2021","journal-title":"Am J Med Sci"},{"issue":"2","key":"pone.0319689.ref022","doi-asserted-by":"crossref","first-page":"00412","DOI":"10.1183\/23120541.00412-2022","article-title":"Effect of acetazolamide on pulmonary vascular haemodynamics in patients with COPD going to altitude: a randomised, placebo-controlled, double-blind trial","volume":"9","author":"M Lichtblau","year":"2023","journal-title":"ERJ Open Res"},{"issue":"1","key":"pone.0319689.ref023","doi-asserted-by":"crossref","first-page":"EVIDoa2100006","DOI":"10.1056\/EVIDoa2100006","article-title":"Acetazolamide to Prevent Adverse Altitude Effects in COPD and Healthy Adults","volume":"1","author":"M Furian","year":"2022","journal-title":"NEJM Evid"},{"issue":"6","key":"pone.0319689.ref024","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1183\/09031936.00216011","article-title":"Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics","volume":"40","author":"A Pichon","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"pone.0319689.ref025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.resp.2008.06.010","article-title":"Effect of acetazolamide on ventilatory response in subjects with chronic mountain sickness","volume":"162","author":"M Rivera-Ch","year":"2008","journal-title":"J Respir Physiol Neurobiol"},{"issue":"23","key":"pone.0319689.ref026","first-page":"00095","article-title":"Early effects of acetazolamide on hemoglobin mass and plasma volume in chronic mountain sickness at 5100 m","author":"B Champigneulle","year":"2023 May 30","journal-title":"Pulmonology"},{"issue":"6","key":"pone.0319689.ref027","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1152\/japplphysiol.00076.2023","article-title":"Possible strategies to reduce altitude-related excessive polycythemia","volume":"134","author":"WFJ Schmidt","year":"2023","journal-title":"J Appl Physiol (1985)"},{"key":"pone.0319689.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resp.2017.07.005","article-title":"Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge\u2019s disease)","volume":"246","author":"S Sharma","year":"2017","journal-title":"Respir Physiol Neurobiol"},{"issue":"12","key":"pone.0319689.ref029","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1164\/rccm.200802-196OC","article-title":"Acetazolamide for Monge\u2019s disease: efficiency and tolerance of 6-month treatment","volume":"177","author":"J-P Richalet","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"pone.0319689.ref030","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1164\/rccm.200505-807OC","article-title":"Acetazolamide: a treatment for chronic mountain sickness","volume":"172","author":"J-P Richalet","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0319689.ref031","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPT Higgins","year":"2019"},{"key":"pone.0319689.ref032","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"pone.0319689.ref033","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1152\/japplphysiol.00443.2015","article-title":"Pharmacology of acute mountain sickness: old drugs and newer thinking","volume":"120","author":"ER Swenson","year":"2016","journal-title":"J Appl Physiol (1985)"},{"key":"pone.0319689.ref034","doi-asserted-by":"crossref","first-page":"681473","DOI":"10.3389\/fmed.2021.681473","article-title":"Acute Hemodynamic Effect of Acetazolamide in Patients With Pulmonary Hypertension Whilst Breathing Normoxic and Hypoxic Gas: A Randomized Cross-Over Trial","volume":"8","author":"M Lichtblau","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"18","key":"pone.0319689.ref035","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1113\/JP281724","article-title":"A change of heart: Mechanisms of cardiac adaptation to acute and chronic hypoxia","volume":"600","author":"AM Williams","year":"2022","journal-title":"J Physiol"},{"key":"pone.0319689.ref036","doi-asserted-by":"crossref","first-page":"1459031","DOI":"10.3389\/fphys.2024.1459031","article-title":"The impact of high-altitude migration on cardiac structure and function: a 1-year prospective study","volume":"15","author":"M-D Deng","year":"2024","journal-title":"Front Physiol"},{"issue":"8","key":"pone.0319689.ref037","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1113\/EP089735","article-title":"Correlation of platelet-derived growth factor and thromboxane A2 expression with platelet parameters and coagulation indices in chronic altitude sickness patients","volume":"107","author":"Y Yin","year":"2022","journal-title":"J Exp Physiol"},{"issue":"6","key":"pone.0319689.ref038","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1152\/japplphysiol.00509.2018","article-title":"Attenuation of human hypoxic pulmonary vasoconstriction by acetazolamide and methazolamide","volume":"125","author":"LM Boulet","year":"2018","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"pone.0319689.ref039","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000536399","article-title":"Effects of 5-Week Oral Acetazolamide on Incremental Cycling Exercise in Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension: A Randomized Placebo-Controlled, Double-Blinded, Crossover Trial","volume":"103","author":"J M\u00fcller","year":"2024","journal-title":"Respiration"},{"issue":"1","key":"pone.0319689.ref040","doi-asserted-by":"crossref","first-page":"e000557","DOI":"10.1136\/bmjresp-2020-000557","article-title":"Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence","volume":"7","author":"CN Schmickl","year":"2020","journal-title":"J BMJ Open Respir Res"},{"issue":"8","key":"pone.0319689.ref041","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2146\/ajhp170279","article-title":"Evaluating off-label uses of acetazolamide","volume":"75","author":"MA Van Berkel","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"pone.0319689.ref042","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s12276-020-00550-2","article-title":"Protective role of estrogen against excessive erythrocytosis in Monge\u2019s disease","volume":"53","author":"P Azad","year":"2021","journal-title":"J Exp Mol Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T17:28:11Z","timestamp":1742318891000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319689"}},"subtitle":[],"editor":[{"given":"Tungki Pratama","family":"Umar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319689","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}